Novo Nordisk looks to shake up diabetes market with new pill-based treatment

Mar 20, 2019

Novo Nordisk has submitted an approval application for a new diabetes pill to the FDA.

Like other diabetes treatments, the new drug is part of a class of blockbuster GLP-1 diabetes medications. But other treatments have to be administered via injected — and for the first time, Novo Nordisk’s drug would offer diabetes patients a once-daily pill. 

Novo Nordisk is banking on the approval of its new treatment to reinvigorate its diabetes portfolio, which will face new generics competition in a few years. 

The treatment received a priority review voucher from the FDA, which could shorten the review time to six months.

Read the full Reuters report.

Looking for insights on the current pharma industry? Download the 2018 State of  Pharmaceutical Manufacturing eBook